Research Analysts Set Expectations for JSPR FY2025 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($4.24) per share for the year. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share.

JSPR has been the subject of a number of other research reports. JMP Securities restated a "market outperform" rating and set a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They set an "outperform" rating and a $63.00 price objective on the stock. Royal Bank of Canada reduced their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday, January 9th. Finally, HC Wainwright dropped their target price on Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $67.75.

Jasper Therapeutics Trading Up 3.9 %

NASDAQ:JSPR traded up $0.22 on Wednesday, reaching $5.92. The stock had a trading volume of 302,744 shares, compared to its average volume of 1,259,690. Jasper Therapeutics has a 12-month low of $5.25 and a 12-month high of $31.01. The stock has a market cap of $88.80 million, a P/E ratio of -1.25 and a beta of 2.18. The company has a 50-day moving average of $18.62 and a 200 day moving average of $19.34.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.15).

Institutional Trading of Jasper Therapeutics

A number of institutional investors have recently made changes to their positions in JSPR. Braidwell LP bought a new stake in Jasper Therapeutics during the third quarter worth approximately $9,091,000. Ally Bridge Group NY LLC raised its stake in shares of Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock worth $7,514,000 after buying an additional 180,852 shares in the last quarter. Samsara BioCapital LLC raised its stake in shares of Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company's stock worth $10,997,000 after buying an additional 59,642 shares in the last quarter. FMR LLC acquired a new stake in shares of Jasper Therapeutics in the third quarter valued at $722,000. Finally, Verition Fund Management LLC bought a new position in Jasper Therapeutics during the third quarter valued at about $477,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.